Stay updated with breaking news from Shanghai Based Dualitybio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Chris Wack Biopharmaceutical companies BioNTech SE and Duality Biologics Co. Ltd. have entered into exclusive license and collaboration agreements to develop, manufacture and commercialize... | April 3, 2023
BioNTech will expand its pipeline into antibody-drug conjugates (ADCs) and deepen its presence in oncology through an up-to-$1.67 billion collaboration with Duality Biologics (DualityBio).
BioNTech’s alliance with DualityBio gives it two antibody drug conjugate (ADC) candidates, the most advanced of which is in mid-stage clinical development for solid tumors. It addresses the same target as a potential blockbuster AstraZeneca drug.